培美曲塞联合顺铂治疗中晚期非小细胞肺癌的有效性及安全性  

Effectiveness and Safety of Pemetrexed Combined with Cisplatin Chemotherapy in Treating Advanced Non-small Cell Lung Cancer

作　　者：王月[1] 金建华[1] 陆文斌[1] 刘迁[1] 

机构地区：[1]江苏大学附属武进人民医院肿瘤科,江苏省常州市213003

出　　处：《实用心脑肺血管病杂志》2017年第7期106-108,共3页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：目的分析培美曲塞联合顺铂治疗中晚期非小细胞肺癌的有效性及安全性。方法选取2012年1月—2014年1月江苏大学附属武进人民医院肿瘤科收治的非小细胞肺癌患者90例,根据治疗方法分为对照组47例和观察组43例。对照组患者采用吉西他滨联合顺铂化疗方案,观察组患者采用培美曲塞联合顺铂化疗方案;两组患者均至少治疗2个化疗周期。比较两组患者近期疗效、生存率及毒副作用发生情况。结果两组患者总缓解率、总控制率比较,差异无统计学意义(P>0.05)。随访1、2、3年两组患者生存率比较,差异无统计学意义(P>0.05)。两组患者Ⅰ~Ⅱ级、Ⅲ~Ⅳ级消化道反应及肝功能损伤发生率比较,差异无统计学意义(P>0.05),而观察组患者Ⅰ~Ⅱ级、Ⅲ~Ⅳ级骨髓抑制发生率低于对照组(P<0.05)。结论培美曲塞联合顺铂与吉西他滨联合顺铂治疗中晚期非小细胞肺癌的近期疗效相当,生存率相似,但培美曲塞联合顺铂化疗方案毒副作用较轻,有利于减少骨髓抑制的发生。Objective To analyze the effectiveness and safety of pemetrexed combined with cisplatin chemotherapy in treating advanced non - small cell lung cancer. Methods From January 2012 to January 2014, a total of 90 patients with advanced non - small cell lung cancer were selected in the Department of Oncology, Wujin People＇s Hospital Affiliated to Jiangsu University, and they were divided into control group （ n =47） and observation group （ n =43） according to therapeutic methods. Patients of control group received gemcitabine combined with cisplatin chemotherapy, while patients of observation group received pemetrexed combined with cisplatin chemotherapy ; both groups treated for 2 cycles of chemotherapy at least. Recent effect, survival rate, incidence of toxic and side effects were compared between the two groups. Results No statistically significant differences of total remission rate or total control rate was found between the two groups （ P 〉 0. 05 ）. No statistically significant differences of survival rate was found between the two groups during the 1 - year, 2 - year or 3 - year follow - up （ P 〉 0. 05） . No statistically significant differences of incidence of Ⅰ - to Ⅱ - grade, Ⅲ - to Ⅳ - grade gastrointestinal reaction or hepatic in injury was found between the two groups （ P 〉 0. 05 ） , while incidence of Ⅰ - to Ⅱ - grade and Ⅲ - to Ⅳ - grade myelosuppression of observation group was statistically significantly lower than that of control group, respectively （P 〈 0. 05 ）. Conclusion Pemetrexed combined cisplatin chemotherapy has similar recent effect and survival rate with gemcitabine combined cisplatin chemotherapy in treating advanced non - small cell lung cancer, but pemetrexed combined cisplatin chemotherapy has relatively milder toxic and side effects, is helpful to reduce the incidence of myelosuppression.

关 键 词：癌 非小细胞肺 培美曲塞 顺铂 治疗结果 药物毒性 

分 类 号：R730.26[医药卫生—肿瘤]